258 related articles for article (PubMed ID: 24009233)
21. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
22. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.
ten Hacken E; Burger JA
Clin Cancer Res; 2014 Feb; 20(3):548-56. PubMed ID: 24323900
[TBL] [Abstract][Full Text] [Related]
23. Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.
Ten Hacken E; Sivina M; Kim E; O'Brien S; Wierda WG; Ferrajoli A; Estrov Z; Keating MJ; Oellerich T; Scielzo C; Ghia P; Caligaris-Cappio F; Burger JA
J Immunol; 2016 Sep; 197(6):2522-31. PubMed ID: 27534555
[TBL] [Abstract][Full Text] [Related]
24. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
25. Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
Giannoni P; Cutrona G; Totero D
Curr Mol Med; 2017; 17(1):24-33. PubMed ID: 28231754
[TBL] [Abstract][Full Text] [Related]
26. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.
Liu TM; Ling Y; Woyach JA; Beckwith K; Yeh YY; Hertlein E; Zhang X; Lehman A; Awan F; Jones JA; Andritsos LA; Maddocks K; MacMurray J; Salunke SB; Chen CS; Phelps MA; Byrd JC; Johnson AJ
Blood; 2015 Jan; 125(2):284-95. PubMed ID: 25293770
[TBL] [Abstract][Full Text] [Related]
27. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
Chen L; Widhopf G; Huynh L; Rassenti L; Rai KR; Weiss A; Kipps TJ
Blood; 2002 Dec; 100(13):4609-14. PubMed ID: 12393534
[TBL] [Abstract][Full Text] [Related]
28. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.
Kennedy E; Coulter E; Halliwell E; Profitos-Peleja N; Walsby E; Clark B; Phillips EH; Burley TA; Mitchell S; Devereux S; Fegan CD; Jones CI; Johnston R; Chevassut T; Schulz R; Seiffert M; Agathanggelou A; Oldreive C; Davies N; Stankovic T; Liloglou T; Pepper C; Pepper AGS
Blood; 2021 Jun; 137(22):3064-3078. PubMed ID: 33512408
[TBL] [Abstract][Full Text] [Related]
29. CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.
Ganghammer S; Hutterer E; Hinterseer E; Brachtl G; Asslaber D; Krenn PW; Girbl T; Berghammer P; Geisberger R; Egle A; Zucchetto A; Kruschinski A; Gattei V; Chigaev A; Greil R; Hartmann TN
Oncotarget; 2015 May; 6(14):12048-60. PubMed ID: 25895128
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
31. Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia.
Butrym A; Gebura K; Iwaszko M; Kuliczkowski K; Bogunia-Kubik K; Mazur G
HLA; 2016 Jun; 87(6):432-8. PubMed ID: 27173875
[TBL] [Abstract][Full Text] [Related]
32. HS1 has a central role in the trafficking and homing of leukemic B cells.
Scielzo C; Bertilaccio MT; Simonetti G; Dagklis A; ten Hacken E; Fazi C; Muzio M; Caiolfa V; Kitamura D; Restuccia U; Bachi A; Rocchi M; Ponzoni M; Ghia P; Caligaris-Cappio F
Blood; 2010 Nov; 116(18):3537-46. PubMed ID: 20530793
[TBL] [Abstract][Full Text] [Related]
33. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen.
Bailón E; Ugarte-Berzal E; Amigo-Jiménez I; Van den Steen P; Opdenakker G; García-Marco JA; García-Pardo A
J Leukoc Biol; 2014 Aug; 96(2):185-99. PubMed ID: 25080557
[TBL] [Abstract][Full Text] [Related]
35. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
36. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.
Troeger A; Johnson AJ; Wood J; Blum WG; Andritsos LA; Byrd JC; Williams DA
Blood; 2012 May; 119(20):4708-18. PubMed ID: 22474251
[TBL] [Abstract][Full Text] [Related]
37. B cell receptor signaling in chronic lymphocytic leukemia.
Burger JA; Chiorazzi N
Trends Immunol; 2013 Dec; 34(12):592-601. PubMed ID: 23928062
[TBL] [Abstract][Full Text] [Related]
38. A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia.
Smith AL; Eiken AP; Skupa SA; Moore DY; Umeta LT; Smith LM; Lyden ER; D'Angelo CR; Kallam A; Vose JM; Kutateladze TG; El-Gamal D
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743155
[TBL] [Abstract][Full Text] [Related]
39. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.
Contri A; Brunati AM; Trentin L; Cabrelle A; Miorin M; Cesaro L; Pinna LA; Zambello R; Semenzato G; Donella-Deana A
J Clin Invest; 2005 Feb; 115(2):369-78. PubMed ID: 15650771
[TBL] [Abstract][Full Text] [Related]
40. ZAP70 expression enhances chemokine-driven chronic lymphocytic leukemia cell migration and arrest by valency regulation of integrins.
Laufer JM; Lyck R; Legler DF
FASEB J; 2018 Sep; 32(9):4824-4835. PubMed ID: 29589978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
